Steroid treatment response to post SARS-CoV-2 PANS symptoms: Case series.
SARS-CoV-2
TIC
neuropsychiatric disorder
pediatric acute-onset neuropsychiatric syndrome (PANS)
steroid
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
10
2022
accepted:
16
01
2023
entrez:
3
3
2023
pubmed:
4
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
Pediatric acute-onset neuropsychiatric syndrome (PANS) is characterized by a wide spectrum of symptoms, including the onset of obsessive-compulsive disorder and/or severely restricted food intake, associated with emotional symptoms, behavioral symptoms, developmental regression, and somatic symptoms. Among the possible triggering agents, infectious agents have been extensively explored. More recently, sporadic case reports describe a possible association between PANS and SARS-CoV-2 infection but data on clinical presentation and treatment are still scarce. We describe a case series (10 children) with acute onset or relapse of PANS symptoms after SARS-CoV-2 infection. Standardized measures (CBCL, CPRS, C-GAS, CGI-S, Y-BOCS, PANSS, and YGTSS) were used to describe the clinical picture. The efficacy of a pulse treatment with steroids for three consecutive months was assessed. Our data suggest that the clinical presentation of the COVID-19-triggered PANS is largely similar to that reported in typical PANS, including acute onset, with OCD and/or eating disorders, and associated symptoms. Our data suggest that treatment with corticosteroids may be beneficial for both global clinical severity and global functioning. No serious adverse effects were observed. Both OCD symptoms and tics consistently improved. Among psychiatric symptoms, affective and oppositional symptoms appeared more sensitive to the steroid treatment than the other symptoms. Our study confirms that COVID-19 infection in children and adolescents could trigger acute-onset neuropsychiatric symptoms. Thus, in children and adolescents with COVID-19, a specific neuropsychiatric follow-up should be routinely included. Even if a small sample size and a follow-up with only two points (baseline and endpoint, after 8 weeks) limit the conclusions, it seems that steroid treatment in the acute phase may be beneficial and well tolerated.
Sections du résumé
Background
UNASSIGNED
Pediatric acute-onset neuropsychiatric syndrome (PANS) is characterized by a wide spectrum of symptoms, including the onset of obsessive-compulsive disorder and/or severely restricted food intake, associated with emotional symptoms, behavioral symptoms, developmental regression, and somatic symptoms. Among the possible triggering agents, infectious agents have been extensively explored. More recently, sporadic case reports describe a possible association between PANS and SARS-CoV-2 infection but data on clinical presentation and treatment are still scarce.
Methods
UNASSIGNED
We describe a case series (10 children) with acute onset or relapse of PANS symptoms after SARS-CoV-2 infection. Standardized measures (CBCL, CPRS, C-GAS, CGI-S, Y-BOCS, PANSS, and YGTSS) were used to describe the clinical picture. The efficacy of a pulse treatment with steroids for three consecutive months was assessed.
Results
UNASSIGNED
Our data suggest that the clinical presentation of the COVID-19-triggered PANS is largely similar to that reported in typical PANS, including acute onset, with OCD and/or eating disorders, and associated symptoms. Our data suggest that treatment with corticosteroids may be beneficial for both global clinical severity and global functioning. No serious adverse effects were observed. Both OCD symptoms and tics consistently improved. Among psychiatric symptoms, affective and oppositional symptoms appeared more sensitive to the steroid treatment than the other symptoms.
Conclusion
UNASSIGNED
Our study confirms that COVID-19 infection in children and adolescents could trigger acute-onset neuropsychiatric symptoms. Thus, in children and adolescents with COVID-19, a specific neuropsychiatric follow-up should be routinely included. Even if a small sample size and a follow-up with only two points (baseline and endpoint, after 8 weeks) limit the conclusions, it seems that steroid treatment in the acute phase may be beneficial and well tolerated.
Identifiants
pubmed: 36864920
doi: 10.3389/fneur.2023.1085948
pmc: PMC9972432
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1085948Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Berloffa, Salvati, Pantalone, Falcioni, Rizzi, Naldini, Masi and Gagliano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Neurol. 2021 Sep 28;12:741176
pubmed: 34650513
World J Psychiatry. 2021 Jul 19;11(7):347-354
pubmed: 34327127
Sci Rep. 2022 Jun 30;12(1):11106
pubmed: 35773312
Lancet Child Adolesc Health. 2021 Jun;5(6):e19-e21
pubmed: 33961798
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
pubmed: 6639293
Neurol Sci. 2020 Oct;41(10):2657-2669
pubmed: 32725449
J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):844-52
pubmed: 9183141
J Am Acad Child Adolesc Psychiatry. 1989 Jul;28(4):566-73
pubmed: 2768151
J Child Adolesc Psychopharmacol. 2015 Feb;25(1):26-30
pubmed: 25695941
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
J Child Adolesc Psychopharmacol. 2017 Sep;27(7):562-565
pubmed: 28722464
J Neurol Sci. 2022 Mar 15;434:120162
pubmed: 35121209
J Abnorm Child Psychol. 1998 Aug;26(4):257-68
pubmed: 9700518
JAMA Neurol. 2021 Dec 1;78(12):1503-1509
pubmed: 34694339
J Child Adolesc Psychopharmacol. 2017 Sep;27(7):629-639
pubmed: 28714753
J Child Adolesc Psychopharmacol. 2020 Oct;30(8):495-511
pubmed: 32460516